Symphogen is a leading clinical late-stage antibody oncology-focused company with a differentiated monoclonal antibody, or mAb, mixture product pipeline with significant clinical potential and commercial opportunities. Their novel biologic approach is uniquely designed to address tumor diversity and resistance by combining multiple antibodies in a single drug product.
